Review
Current management and novel agents for malignant melanoma
-
* Corresponding author: Delong Liu delong_liu@nymc.edu
Division of Hematology and Oncology, New York Medical College and Westchester Medical Center, Valhalla, New York 10595, USA
Journal of Hematology & Oncology 2012, 5:3 doi:10.1186/1756-8722-5-3
Published: 14 February 2012Abstract
Advanced malignant melanoma remains a challenging cancer. Over the past year, there have been 3 agents approved for treatment of melanoma by Food and Drug Administration. These include pegylated interferon alpha-2b for stage III melanoma, vemurafenib for unresectable or metastatic melanoma with BRAF V600E mutation, and ipilimumab for treatment of unresectable or metastatic melanoma. This review will also update on the development of novel agents, including tyrosine kinase inhibitors and adoptive cellular therapy.